Ray Therapeutics, a clinical-stage biopharmaceutical company pioneering vision restoration, has announced the successful closure of an oversubscribed $125 million Series B financing. This significant capital injection, led by Janus Henderson Investors, is earmarked to advance the company's pipeline of optogenetic therapies for severe retinal degenerations. The funding arrives on the heels of the U.S. Food and Drug Administration granting Regenerative Medicine Advanced Therapy (RMAT) Designation to its lead program.
A Vote of Confidence from Leading Investors
The financing round attracted a syndicate of esteemed new investors, including Adage Capital Management, Franklin Templeton, Invus, and Marshall Wace. This robust participation was led by Janus Henderson Investors, a firm known for identifying value-creating biopharmaceutical companies. The oversubscribed nature of the round highlights the compelling nature of Ray Therapeutics' technology and its potential to address a major unmet medical need.
Strong continued support from existing investors further solidified the financing, with participation from 4BIO Capital, Deerfield Management, and Novo Holdings A/S. MRL Ventures Fund, the corporate venture arm of Merck & Co, also contributed, signaling confidence from established pharmaceutical players. This blend of new and returning investors provides Ray Therapeutics with a powerful financial foundation for its next phase of growth.
Pioneering Optogenetic Gene Therapy
At the core of the company's strategy is a cutting-edge optogenetic platform designed to function independently of the specific genetic mutations causing blindness. The therapy involves delivering a bioengineered, highly light-sensitive protein to specific retinal cells using a gene therapy vector. This approach effectively turns the targeted cells into new photoreceptors, creating a pathway to restore visual function in patients.
The treatment is administered as a single intravitreal injection, a common and relatively non-invasive procedure performed in an ophthalmologist's office. This delivery method is designed to provide a durable, long-term effect, potentially eliminating the need for repeated treatments. By targeting remaining retinal cells, the therapy offers hope to individuals who have lost their natural photoreceptors and have limited treatment options.
Advancing a Multi-Program Clinical Pipeline
The company's lead candidate, RTx-015, is currently under evaluation in a clinical study for patients with retinitis pigmentosa. Its recent RMAT designation by the FDA is a significant milestone that can expedite the development and review process for this promising therapy. This designation is reserved for therapies intended to treat serious conditions where preliminary clinical evidence indicates potential to address unmet medical needs.
Beyond its lead program, Ray Therapeutics is also developing RTx-021, a second clinical-stage asset targeting diseases of the macula. This therapy is specifically designed to restore vision in patients with conditions like Stargardt disease and geographic atrophy. By targeting retinal bipolar cells, RTx-021 expands the potential application of the company's optogenetic platform to a broader patient population.
A Vision for a New Standard of Care
Paul Bresge, CEO and Co-Founder of Ray Therapeutics, stated that the funding is a decisive endorsement of the company's platform. He emphasized that it validates the clinical and regulatory momentum achieved to date and reinforces their commitment to patients. Agustin Mohedas of Janus Henderson Investors echoed this sentiment, calling the technology a potential "first and best-in-class" approach.
With this substantial $125 million in Series B funding, Ray Therapeutics is strongly capitalized to push its innovative vision restoration therapies through critical clinical trials. The broad support from a distinguished group of investors validates the company's differentiated optogenetic platform and its potential to transform patient care. This financial milestone moves the company closer to its goal of delivering life-changing treatments for those living with blinding retinal diseases.